Cover Image
市場調查報告書

T細胞免疫療法:臨床實驗追蹤分析

T-cell Immunotherapy: Clinical Trial Tracker

出版商 ROOTS ANALYSIS 商品編碼 364508
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
T細胞免疫療法:臨床實驗追蹤分析 T-cell Immunotherapy: Clinical Trial Tracker
出版日期: 2016年07月11日 內容資訊: 英文
簡介

使用T細胞的免疫療法相關研究,隨著主治療的開發和上市,轉移到成熟階段。而且,預期T細胞免疫療法的市場今後將大幅度成長。市場仍處於初期階段,還沒有上市產品,不過,有複數產品達到臨床實驗的最後階段。

本報告提供T細胞免疫療法相關臨床實驗最新趨勢相關分析,產業整體臨床實驗趨勢和近幾年的主要動向,各領域 (CAR-T、TCR、TIL)的詳細資訊,臨床實驗的主要促進、阻礙因素,最後階段的主要開發中產品,今後的市場趨勢預測的資訊彙整,為您概述為以下內容。

目錄

  • 市場概要
  • 整體情形:開發中產品及臨床實驗分析
  • 嵌合抗原受體表現T細胞療法 (CAR-T):臨床實驗的進展
  • T細胞受體 (TCR):臨床實驗的進展
  • 腫瘤內浸潤淋巴球療法 (TIL):臨床實驗的進展
  • 市場預測的前提條件
  • 市場趨勢的預測 (今後16年份)
  • 臨床試驗前
  • 分析對象的編入/除外標準
  • 簡稱一覽

圖表一覽

分析對象企業一覽 (共159家公司、團體)

目錄
Product Code: CT10005

After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. These promising therapeutic strategies, developed under the banner of T-cell immunotherapies, are set to hit the market in the near future.T-cells, also named as the soldiers of the immune system, are featured with specificity and functionally combat infections, cancerous cells and other foreign entities. High therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy.

With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time, expertise and effort, have played a critical role in maturing the design and development of novel CAR-Ts, TCRs and TILs. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania/The Children's Hospital of Philadelphia), JCAR017 (Juno Therapeutics/Seattle Children's Hospital), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), CD19-CAR (Takara Bio/Jichi Medical University) and LN-144 (Lion Biotechnologies/National Cancer Institute).

Synopsis:

The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of T-cell Immunotherapy. We have identified a number of T-cell Immunotherapy products and clinical trials that are either being conducted or planned to be conducted for each of these products. For each specific product, we have provided the following information:

  • 1. Primary Drug
  • 2. Highest Phase of Development
  • 3. Developer/Licensee
  • 4. Target Antigen

For each specific trial, we have provided the following information:

  • 1. Indication
  • 2. Type of Indication
  • 3. Sponsor/Collaborator
  • 4. Type of Sponsor
  • 5. Trial Title
  • 6. Trial Objective
  • 7. Trial Phase
  • 8. Trial Status
  • 9. Start Date
  • 10. End Date
  • 11. Enrolment
  • 12. Age Range
  • 13. Inclusion Criteria
  • 14. Exclusion Criteria
  • 15. StudyDesign
  • 16. PrimaryEndpoint
  • 17. SecondaryEndpoint
  • 18. Treatment Arm(s)
  • 19. Location(s)
  • 20. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

  • Sales forecasts of the T-cell Immunotherapy market over the course of next fifteen years. Owing to the emerging nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

Research Methodology

The data presented in this report has been gathered via secondary research. The secondary sources of information include

  • Clinical trial registries
    • Clinicaltrials.gov
    • International Clinical Trials Registry Platform (ICTRP)
    • EU Clinical Trials Register (EU CTR)
    • Chinese Clinical Trial Register (ChiCTR)
  • Annual reports
  • Investor presentations
  • SEC filings
  • Company websites
  • Conference websites
  • Industry analyst's views

The focus has been on capturing the details on completed and ongoing clinical trials for T-cell immunotherapy. The report also provides an in-depth analysis of the competitive landscape for both pipeline molecules and clinical trials. The analysis is solely based on our knowledge and research gathered from various secondary sources of information.

Table of Contents

Introduction and Pipeline Details

  • 1. Market Overview
  • 2. Dashboard: Pipeline and Trial Analysis
  • 3. CAR-T Clinical Development: Trial Details
  • 4. TCR Clinical Development: Trial Details
  • 5. TIL Clinical Development: Trial Details
  • 6. Market Forecast: Assumptions
  • 7. Market Forecast, 2015-2030
  • 8. Preclinical Development
  • 9. Inclusion / Exclusion Criteria
  • 10. Abbreviations

List of Figures

Pipeline and Trial Details

  • Figure 1: T-cell Immunotherapy Products in Clinical Development: Distribution by Type of Therapy
  • Figure 2: T-cell Immunotherapy Trialsin Clinical Development: Distribution by Type of Therapy
  • Figure 3: T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development
  • Figure 4: T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development and Type of Therapy
  • Figure 5: T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area
  • Figure 6: T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
  • Figure 7: T-cell Immunotherapy Products in Clinical Development: Distribution by Target in the CAR-T Market
  • Figure 8: T-cell Immunotherapy Products in Clinical Development: Distribution by Targets in the TCR Market
  • Figure 9: T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for CAR-T Therapy
  • Figure 10: T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for TCR Therapy
  • Figure 11: T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development
  • Figure 12: T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development and Type of Therapy
  • Figure 13: T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area
  • Figure 14: T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
  • Figure 15: T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status
  • Figure 16: T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status and Type of Therapy
  • Figure 17: T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship
  • Figure 18: T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship and Type of Therapy
  • Figure 19: T-cell Immunotherapy Trials in Clinical Development: Distribution by Region
  • Figure 20: T-cell Immunotherapy Trials in Clinical Development: Distribution by Region and Type of Therapy
  • Figure 21: T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries
  • Figure 22: T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries and Type of Therapy

Market Forecast Analysis

  • Figure A: T-cell Immunotherapy Market Forecast, 2015-2030
  • Figure B: T-cell Immunotherapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million)

List of Tables

Pipeline Details

  • Table 1: CAR-T Clinical Development: Pipeline Details
  • Table 2: TCR Clinical Development: Pipeline Details
  • Table 3: TIL Clinical Development: Pipeline Details
  • Table 4: Preclinical Development

Market Forecast Analysis

  • Table A Market Forecast: Assumptions

Listed Companies

The following companies and organisations have been mentioned in the report:

  • 1. Abramson Cancer Center of the University of Pennsylvania
  • 2. Adaptimmune
  • 3. Affiliated Hospital to Academy of Military Medical Sciences
  • 4. Agency for Science, Technology and Research, China
  • 5. Albert Einstein College of Medicine, Yeshiva University
  • 6. Alex's Lemonade Stand Foundation
  • 7. Altor Biosciences
  • 8. Amgen
  • 9. Anhui General Hospital of Armed Police Forces
  • 10. Anhui Medical University & Hospital
  • 11. AstraZeneca/MedImmune
  • 12. Atreca Therapeutics
  • 13. Autolus
  • 14. Baxalta
  • 15. Beijing Doing Biomedical
  • 16. Bellicum Pharmaceuticals
  • 17. bluebird bio
  • 18. Bristol Myers Squibb
  • 19. California Institute of Technology
  • 20. Cancer Prevention Research Institute of Texas
  • 21. Cancer Research UK
  • 22. CARsgen Therapeutics
  • 23. Celdara Medical
  • 24. Celgene
  • 25. Cell Therapy Catapult
  • 26. Cellectis
  • 27. Cellular Biomedicine Group
  • 28. Celyad
  • 29. Center for Cell and Gene Therapy, Baylor College of Medicine
  • 30. Changzheng Hospital
  • 31. Children's Mercy Hospital, Kansas City
  • 32. Chinese PLA General Hospital
  • 33. Christie Hospital NHS Foundation Trust
  • 34. City of Hope Medical Center
  • 35. Clinica Universidad de Navarra
  • 36. CLL Global Research Foundation Alliance
  • 37. Conkwest
  • 38. Copenhagen University Hospital
  • 39. Cornell Weill Medicine, Cornell University
  • 40. Dana-Farber Cancer Institute
  • 41. Duke University Medical Center
  • 42. Erasmus Medical Center
  • 43. Fate Therapeutics
  • 44. First Hospital of Jilin University
  • 45. Five Prime Therapeutics
  • 46. Formula Pharmaceuticals
  • 47. Fred Hutchinson Cancer Research Center
  • 48. Fuda Cancer Hospital
  • 49. Fudan University Shanghai Cancer Center
  • 50. Glaxo Smith Kline
  • 51. H. Lee Moffitt Cancer Center and Research Institute
  • 52. Hadassah Medical Organization
  • 53. Harlev Hospital
  • 54. Hefei Binhu Hospital
  • 55. Hoag Memorial Hospital Presbyterian
  • 56. Huazhong University of Science and Technology
  • 57. iCarTAb BioMed
  • 58. iCell Therapeutics
  • 59. Immatics
  • 60. Immunocore
  • 61. Intrexon Corporation
  • 62. James and Esther King Biomedical Research Program
  • 63. Janssen Pharmaceuticals
  • 64. Jichi Medical University
  • 65. John Wayne Cancer Institute
  • 66. Jonsson Comprehensive Cancer Center
  • 67. Juno Therapeutics
  • 68. JW Biotechnology
  • 69. Karolinska University Hospital
  • 70. Key Biologics
  • 71. King's College London
  • 72. Kite Pharma
  • 73. Leiden University
  • 74. Leukaemia Lymphoma Research
  • 75. Lion Biotechnologies
  • 76. Lion TCR
  • 77. M.D. Anderson Cancer Center
  • 78. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • 79. MaxCyte Therapeutics
  • 80. MediGene
  • 81. Memorial Sloan Kettering Cancer Center
  • 82. Mie University
  • 83. Military Medical University
  • 84. Molmed S.p.A
  • 85. Mustang Bio
  • 86. Nantes University & Hospital
  • 87. Nantworks
  • 88. National Cancer Institute
  • 89. National Health and Medical Research Council
  • 90. National Heart, Lung, and Blood Institute
  • 91. National Institutes of Health
  • 92. Novartis
  • 93. Oxford BioMedica
  • 94. Peking University
  • 95. PersonGen Biomedicine
  • 96. Peter MacCallum Cancer Centre
  • 97. Pfizer
  • 98. Poseida Therapeutics
  • 99. Precision BioSciences
  • 100. Prometheus
  • 101. RenJi Hospital
  • 102. Roger Williams Medical Center
  • 103. Roswell Park Cancer Institute
  • 104. Royal Adelaide Hospital Cancer Centre
  • 105. San Raffaele Hospital
  • 106. Seattle Children's Hospital
  • 107. Seattle Genetics
  • 108. Servier
  • 109. Shanghai GeneChem
  • 110. Shanghai Jiao Tong University
  • 111. Shanghai Tongji Hospital and University
  • 112. Sheba Medical Center
  • 113. Shenzhen Institute for Innovation and Translational Medicine
  • 114. Shenzhen Second People's Hospital
  • 115. Shionogi
  • 116. Sidney Kimmel Comprehensive Cancer Center
  • 117. Singapore General Hospital
  • 118. Sinobioway Cell Therapy
  • 119. Sirtex Medical
  • 120. Solving Kid's Cancer
  • 121. Southwest Hospital
  • 122. St. Luke's Medical Center
  • 123. Sun Yat-Sen University
  • 124. Swedish Cancer Society
  • 125. Takara Bio
  • 126. Texas Children's Hospital
  • 127. The EVAN Foundation
  • 128. The First People's Hospital of Hefei
  • 129. The Methodist Hospital System
  • 130. The Netherlands Cancer Institute
  • 131. The Second Military Medical University
  • 132. The Third Military Medical University
  • 133. Theravectys
  • 134. Tianjin Medical University Cancer Institute and Hospital
  • 135. TILT Biotherapeutics
  • 136. TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
  • 137. UNC Lineberger Comprehensive Cancer Center
  • 138. Universal Cells
  • 139. University College London
  • 140. University Health Network, Toronto
  • 141. University of Colorado
  • 142. University of Connecticut
  • 143. University of Florida
  • 144. University of Manchester
  • 145. University of Maryland Greenebaum Cancer Center
  • 146. University of Pennsylvania
  • 147. University of Southern California
  • 148. University of Zurich
  • 149. Unum Therapeutics
  • 150. Uppsala University
  • 151. ViroMed
  • 152. West China Hospital, Sichuan University
  • 153. Wuhan General Hospital of Guangzhou Command
  • 154. WuXi AppTec
  • 155. Xinqiao Hospital of Chongqing
  • 156. Xuzhou Medical College
  • 157. Zhejiang General Hospital of Armed Police
  • 158. Zhujiang Hospital
  • 159. Ziopharm Oncology
Back to Top